Evidence map›Paper›PMID 37986801›Full record

ArticlebioRxiv : the preprint server for biology2023

2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer.

Shannon Coy, Brian Cheng, Jong Suk Lee, Rumana Rashid, Lindsay Browning, Yilin Xu, Sankha S Chakrabarty, Clarence Yapp, Sabrina Chan, Juliann B Tefft and 7 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Targeting chromosomal instability in patients with cancer.Nature reviews. Clinical oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Shannon CoyLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0033-9031
Brian ChengLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9842-6610
Jong Suk LeeLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0009-0008-4460-7118
Rumana RashidLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6986-7209
Lindsay BrowningLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5697-8890
Yilin XuLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0009-0002-5696-7475
Sankha S ChakrabartyLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0004-2254
Clarence YappLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1144-5710
Sabrina ChanLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4557-2972
Juliann B TefftLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8826-665X
Emily ScottLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Alexander SpektorDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1085-3205
Keith L LigonDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7733-600X
Gregory J BakerLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5196-3961
David PellmanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-5306-8031
Peter K SorgerLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3364-1838
Sandro SantagataLudwig Center at Harvard, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7528-9668
Brigham and Women's Hospital · USHarvard University · USHoward Hughes Medical Institute · US

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5M
TRAINING GRANT IN GENETICST32GM007748 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Anne O'Donnell-Luria, Louise Wilkins-Haug · 1985 to 2026
$12.0M
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2018 to 2022
$10.8M
MOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6M
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO, SORGER, PETER KARL · 2018 to 2023
$8.7M
Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Targeting the neuronal microenvironment in glioblastomaU19CA264504 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL J ECK · 2021 to 2026
$6.4M
Polyploidy, Aneuploidy and Genome StabilityR01CA213404 · NCI · DANA-FARBER CANCER INST · PI PELLMAN, DAVID S · 2017 to 2024
$3.5M
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine GliomasR01CA219943 · NCI · BROAD INSTITUTE, INC. · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.5M
NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA188228NCI NIH HHS R01 CA213404NCI NIH HHS R01 CA219943NCI NIH HHS T32 CA009216NCI NIH HHS U19 CA264504NCI NIH HHS U2C CA233262NCI NIH HHS U54 CA225088NIGMS NIH HHS T32 GM007748
6 · The paper itself

Abstract

Nuclear atypia, including altered nuclear size, contour, and chromatin organization, is ubiquitous in cancer cells. Atypical primary nuclei and micronuclei can rupture during interphase; however, the frequency, causes, and consequences of nuclear rupture are unknown in most cancers. We demonstrate that nuclear envelope rupture is surprisingly common in many human cancers, particularly glioblastoma. Using highly-multiplexed 2D and super-resolution 3D-imaging of glioblastoma tissues and patient-derived xenografts and cells, we link primary nuclear rupture with reduced lamin A/C and micronuclear rupture with reduced lamin B1. Moreover, ruptured glioblastoma cells activate cGAS-STING-signaling involved in innate immunity. We observe that local patterning of cell states influences tumor spatial organization and is linked to both lamin expression and rupture frequency, with neural-progenitor-cell-like states exhibiting the lowest lamin A/C levels and greatest susceptibility to primary nuclear rupture. Our study reveals that nuclear instability is a core feature of cancer, and links nuclear integrity, cell state, and immune signaling.

Identifiers

PMID37986801
PMCPMC10659270
OpenAlexW4388599493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.